Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway

BACKGROUND: Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a new class of antidiabetic drugs that exhibit multiple extraglycemic effects. However, there are conflicting results regarding the effects of SGLT2 inhibition on energy expenditure and thermogenesis. Therefore, we investigated the e...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Ji-Yeon, Lee, Minyoung, Lee, Ji Young, Bae, Jaehyun, Shin, Eugene, Lee, Yong-ho, Lee, Byung-Wan, Kang, Eun Seok, Cha, Bong-Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Diabetes Association 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640151/
https://www.ncbi.nlm.nih.gov/pubmed/33611885
http://dx.doi.org/10.4093/dmj.2020.0187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640151/
https://www.ncbi.nlm.nih.gov/pubmed/33611885
http://dx.doi.org/10.4093/dmj.2020.0187

Ejemplares similares